What You Need to Know:
Most individuals, depending on age, previously vaccinated with a monovalent COVID-19 vaccine who have not yet received a dose of a bivalent vaccine may receive a single dose of a bivalent vaccine.
1/2
Most individuals who have already received a single dose of the bivalent vaccine are not currently eligible for another dose. The FDA intends to make decisions about future vaccination after receiving recommendations on the fall strain composition at an FDA advisory committee in June.
Individuals 65 years of age and older who have received a single dose of a bivalent vaccine may receive one additional dose at least four months following their initial bivalent dose.
2/3
Most individuals w/ certain kinds of immunocompromise who have received a bivalent C19 vaccine may receive a single additional dose of a bivalent C19 vaccine at least 2 months following a dose of a bivalent C19 vaccine, and additional doses may be administered at the discretion of, and at intervals determined by, their healthcare provider. However,for immunocompromised individuals 6 months through 4 yrs old, eligibility for additional doses will depend on the vaccine previously received.
3/4
Most unvaccinated individuals may receive a single dose of a bivalent vaccine, rather than multiple doses of the original monovalent mRNA vaccines.
4/5
Children 6 months through 5 years of age who have received one, two or three doses of a monovalent COVID-19 vaccine may receive a bivalent vaccine, but the number of doses that they receive will depend on the vaccine and their vaccination history.
6/6
There is a bit more details on the Main page of the FDA website, here you go ...
Children 6 months through 5 years of age who are unvaccinated may receive a two-dose series of the Moderna bivalent vaccine (6 months through 5 years of age) OR a three-dose series of the Pfizer-BioNTech bivalent vaccine (6 months through 4 years of age). Children who are 5 years of age may receive two doses of the Moderna bivalent vaccine or a single dose of the Pfizer-BioNTech bivalent vaccine.
5/6